Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Vatalanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 known ✓ | P17948 | 19/20 | 0.97 |
| ▸ | KDR known ✓ | P35968 | 19/20 | 0.97 |
| ▸ | PDGFRB known ✓ | P09619 | 9/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 8/20 | 0.97 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 0.97 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.97 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.97 |
| ▸ | CIT | O14578 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | HLA-A | P04439 | 1/20 | 0.97 |
| ▸ | RET | P07949 | 1/20 | 0.97 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.97 |
| ▸ | FRK | P42685 | 1/20 | 0.97 |
| ▸ | CDK8 | P49336 | 1/20 | 0.97 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.97 |
| ▸ | STK3 | Q13188 | 1/20 | 0.97 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.97 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.97 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.97 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatalanib SCHEMBL905616 | 1.00 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905598 | 1.00 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL18286 | 0.99 | FLT1 (1.00) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29350047 | 0.99 | FLT1 (1.00) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131019 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131018 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131017 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL28147347 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.92 | KDR (0.88) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6607537 | 0.91 | KDR (0.84) | FLT1KDRPDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250283077-A1 | ENHANCED HAMMERHEAD RIBOZYMES AND METHODS OF USE | US GOV VETERANS AFFAIRS (US) | 2025-09-11 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| WO-2025051110-A1 | COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES | INSILICO MEDICINE IP LIMITED (CN) | 2025-03-13 | — | — | WO | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | disclosed |
| US-11980667-B2 | Short TAT oligomers for drug delivery | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4279064-A2 | DRUG DELIVERY FROM HYDROGELS | Incept, LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3294212-B1 | DRUG DELIVERY FROM HYDROGELS | INCEPT LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20230136878-A1 | CARDIOMYOCYTE PURIFICATION METHOD | Orizuru Therapeutics, Inc. (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4123015-A1 | CARDIOMYOCYTE PURIFICATION METHOD | Orizuru Therapeutics, Inc. (JP) | 2023-01-25 | — | — | EP | disclosed |
| US-20220370419-A1 | DRUG DELIVERY FROM HYDROGELS | INCEPT, LLC | 2022-11-24 | — | — | US | disclosed |
| US-11369591-B2 | Drug delivery from hydrogels | INCEPT, LLC (US) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | FLT1 984/4885KDR 1464/4885PDGFRB 254/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | FLT1 1127/4885KDR 1552/4885PDGFRB 234/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | FLT1 55/4885KDR 32/4885PDGFRB 300/4885 |
| US-11980667-B2 | Short TAT oligomers for drug delivery | ACIN1, MYCBP, STAT3 | FLT1 568/4885KDR 303/4885PDGFRB 1869/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | FLT1 636/4885KDR 726/4885PDGFRB 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.